AX-2025-019648 · GHRP-2 · TFC lot TFC-2502-D2333

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 25 min gradient, 214 nm	99.41	% area	≥ 99.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.59	% area	≤ 1.0	PASS
Largest single impurity	RP-HPLC — des-Lys (−128 Da)	0.33	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	817.4275	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, unit resolution (single quadrupole)	817.4266	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-1.1	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	5.67	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	7.42	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.54	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	6.85	EU/mg	≤ 5.0	FAIL
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White to pale-yellow cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Faint haze, clearing on standing	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.48	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 25 min gradient	7.59	min	7.67 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.12	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	50,408	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-2-Nal]-epimer	0.84	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 25 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 50,408, and skew follows the reported asymmetry factor of 1.12. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.33 % impurity against a 99.41 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	GHRP-2 — main peak	7.59	4,831,634	99.41	—
2	des-Lys (−128 Da)	7.39	16,039	0.33	-128.095
3	oxidised Trp (+16 Da)	7.29	7,290	0.15	+15.995
4	[D-2-Nal]-epimer	7.47	2,916	0.06	0.000
5	C-terminal free acid (+1 Da)	7.72	2,430	0.05	+0.984
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 817.4275 Da, computed from C45H55N9O6. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, unit-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 817.4266 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	409.7210	409.7206	-0.0004	56.0
1+	818.4348	818.4339	-0.0009	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.38	99.41	divergence -0.25 pp vs batch median
Total impurities (% area)	0.62	0.59
Largest single impurity (% area)	0.27	0.33
Water (%)	4.5	5.67
Counter-ion (%)	not stated	7.42
Peptide content (%w/w)	not stated	not determined
Endotoxin (EU/mg)	not stated	6.85
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (ambient, 5 d) → laboratory (hand-carried, 5 d) → assay.
Assay date: 07 Jan 2025
Submitted to the index: 10 Jan 2025
Laboratory: Medutest, Ljubljana, Slovenia
Method basis: 25 min gradient · unit-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

That the compound is not a near-isobaric alternative. Identity was confirmed at unit mass resolution, which cannot exclude species differing by 1 or 2 Da. The specific alternatives not excluded are named in the identity block above.
How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

area_percent10 Jan 2025

Area percent assumes unit response factors across every species present. At 99.41 % the assumption barely matters — there is not enough impurity for a response-factor error to move the figure by a tenth.

gradient_2510 Jan 2025

The gradient is on the record, which is the first thing that should be true of any purity figure and often is not. 25 min at Medutest puts this comparison on a documented footing.

sodium_adduct10 Jan 2025

Adduct bookkeeping on this one is tidy. The sodium series is present at the expected intensity ratio and has not been counted as an impurity, which happens more often than it should.

units_pedant10 Jan 2025

Reported as signed ppm, which is the right convention: direction carries information about calibration that a modulus discards.

Section 7

Related records

Same batch — lot TFC-2502-D2333 n=12

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-019643	TFC-2502-D2333	Nordanalyt	2025-Q1	99.93	5.03	105.4	Supplier-supplied	0	PASS
AX-2025-019644	TFC-2502-D2333	Janoshik	2025-Q1	99.64	5.17	105.6	Buyer-sourced	0	PASS
AX-2025-019645	TFC-2502-D2333	Kestrel	2025-Q1	99.93	4.78	—	Buyer-sourced	0	PASS
AX-2025-019646	TFC-2502-D2333	Janoshik	2025-Q1	99.82	5.76	93.2	Buyer-sourced	0	PASS
AX-2025-019647	TFC-2502-D2333	PeptideMeter	2025-Q1	99.32	5.48	98.6	Buyer-sourced	0	PASS
AX-2025-019649	TFC-2502-D2333	Janoshik	2025-Q1	99.40	4.89	93.8	Buyer-sourced	0	PASS
AX-2025-019650	TFC-2502-D2333	Janoshik	2025-Q1	99.36	5.50	104.7	Buyer-sourced	0	PASS
AX-2025-019651	TFC-2502-D2333	Medutest	2025-Q1	99.72	5.07	98.7	Buyer-sourced	0	PASS
AX-2025-019652	TFC-2502-D2333	Kestrel	2025-Q1	99.61	5.36	88.7	Buyer-sourced	1	MARGINAL
AX-2025-019653	TFC-2502-D2333	Janoshik	2025-Q1	99.87	5.35	—	Buyer-sourced	0	PASS
AX-2025-019654	TFC-2502-D2333	Medutest	2025-Q1	99.36	5.26	93.0	Buyer-sourced	1	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent GHRP-2 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043535	SIG	SIG-2603-6031	Janoshik	2026-Q3	99.12	1.26	105.7	Buyer-sourced	0	PASS
AX-2026-043541	SIG	SIG-2603-6031	PeptideMeter	2026-Q3	99.06	2.08	107.4	Buyer-sourced	1	MARGINAL
AX-2026-043539	SIG	SIG-2603-6031	Janoshik	2026-Q3	98.95	1.74	100.4	Buyer-sourced	1	FAIL
AX-2026-043534	SIG	SIG-2603-6031	Medutest	2026-Q3	99.11	2.15	89.8	Buyer-sourced	1	MARGINAL
AX-2026-043542	SIG	SIG-2603-6031	VendorInvestigate	2026-Q3	99.05	1.43	—	Buyer-sourced	1	FAIL
AX-2026-043543	SIG	SIG-2603-6031	Janoshik	2026-Q3	99.38	1.70	98.6	Buyer-sourced	0	PASS
AX-2026-043544	SIG	SIG-2603-6031	PeptideMeter	2026-Q3	99.57	1.51	105.4	Buyer-sourced	0	PASS
AX-2026-043538	SIG	SIG-2603-6031	Kestrel	2026-Q3	98.93	1.72	—	Buyer-sourced	0	FAIL

Other recent TFC records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042265	Humanin (HNG)	TFC-2605-U1300	PeptideMeter	2026-Q3	99.52	6.31	—	Buyer-sourced	0	PASS
AX-2026-042222	SS-31 (Elamipretide)	TFC-2607-R9099	VendorInvestigate	2026-Q3	99.46	5.41	102.6	Buyer-sourced	0	PASS
AX-2026-042236	Humanin (HNG)	TFC-2608-S9940	Nordanalyt	2026-Q3	98.64	1.80	—	Buyer-sourced	0	PASS
AX-2026-042282	Retatrutide	TFC-2608-J1156	Janoshik	2026-Q3	98.54	4.27	—	Buyer-sourced	0	PASS
AX-2026-042226	SS-31 (Elamipretide)	TFC-2607-R9099	Janoshik	2026-Q3	99.62	5.47	—	Buyer-sourced	0	PASS
AX-2026-042217	Semaglutide	TFC-2604-X9037	PeptideMeter	2026-Q3	98.95	4.61	96.9	Buyer-sourced	0	PASS
AX-2026-042339	Sermorelin	TFC-2605-Y2176	Kestrel	2026-Q3	99.93	4.14	—	Supplier-supplied	1	FAIL
AX-2026-042214	Semaglutide	TFC-2604-X9037	Kestrel	2026-Q3	99.87	4.66	103.1	Laboratory-retained	0	PASS